Signature Global to launch IPO on September 20

| Leave a Comment | IPO

Real estate developer Signature Global (India) will launch its initial public offering (IPO) on September 20 to raise Rs 730 crore. The price band will be announced in the coming days.

The IPO will consist of fresh shares worth Rs 603 crore from the company and an offer-for-sale (OFS) of Rs 127 crore from the International Finance Corporation (IFC).

The offer will close on September 22. The issue size has been reduced from Rs 1,000 crore in July last year.

Signature Global is the largest real estate development company in the National Capital Region of Delhi (Delhi NCR) in the affordable and lower mid-segment housing. The company has sold 27,965 residential and commercial units, all within the Delhi NCR region.

The company plans to use the net proceeds from the IPO to repay debts amounting to Rs 432 crore, while the rest will be used for inorganic growth through land acquisitions and general corporate purposes.

Up to 75 percent of the issue size has been reserved for qualified institutional buyers (QIB), and up to 60 percent of it is reserved for anchor investors who can book shares on September 18. The remaining 15 percent of the issue size is reserved for high net-worth individuals and 10 percent for retail investors.

The IPO is being managed by ICICI Securities, Axis Capital, and Kotak Mahindra Capital Company. Link Intime India is the registrar to the offer.

Key details of the IPO:

  • Issue size: Rs 730 crore
  • Fresh issue: Rs 603 crore
  • Offer-for-sale: Rs 127 crore
  • Price band: To be announced
  • Opening date: September 20
  • Closing date: September 22
  • Lead merchant bankers: ICICI Securities, Axis Capital, and Kotak Mahindra Capital Company
  • Registrar to the offer: Link Intime India

Risk factors to consider:

  • The company has a history of losses. It recorded a consolidated net loss of Rs 63.7 crore for the year ended March FY23.
  • The company is highly leveraged. Its debt-equity ratio stood at 2.34 as of March FY23.
  • The real estate sector is cyclical and subject to regulatory changes.


Signature Global is a leading real estate developer in the Delhi NCR region. The company has a strong track record of sales and execution. However, investors should be aware of the risks associated with the IPO, such as the company’s history of losses and its high debt levels.


Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Unihealth Consultancy makes tepid debut on NSE Emerge

    Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.

Leave a Reply

Your email address will not be published. Required fields are marked *